Early Detection

Skin cancer can occur at any time and your chances of surviving melanoma depends on how deep it has gone. We use a measurement called the Breslow Thickness.

To demonstrate, the average depth at which Molemap by Dermatologists can identify melanoma is 0.6mm, which gives nearly 100% chance of survival in 5 years. The average of other skin check providers reduces your chances of survival to 90%*.

Highly Accurate

Because Molemap is highly accurate at identifying melanoma, there’s less need to recommend surgically removing benign (harmless) moles. With Molemap, the ratio of benign moles removed to find one melanoma is <5:1*

This means less scars for you. Elsewhere twenty moles may need to be removed to find one melanoma.

Advanced Technology

Most skin cancers such as melanoma are difficult to detect with the naked eye. Our advanced dermoscopic technology looks deep inside a mole’s structure to detect skin changes early. And our advanced skin-mapping technology is designed to spot skin cancers earlier than visual checks.

The Original Molemap

The term molemap was first coined by us – Molemap by Dermatologists – back in 1997. It then became a commonly used term before we were able to trademark it.

Our experience, clinical excellence, world-leading technology, low benign to malignant ratio, and our ability to detect melanoma early, means you are in trusted hands at Molemap by Dermatologists. The original and the best.

World Renowned

Molemap’s data is so respected, it is used for studies and educational programs at world-leading cancer centres including the Mayo Clinic in the USA and the Memorial Sloane-Kettering Cancer Clinic (MSKCC).

A Molemap published study (The “Ugly Duckling” Sign) found that identifying pigmented moles that look different from a person’s other moles – the “ugly duckling” sign – is a practical way to spot malignant skin cancer. This study made headlines around the world.
https://jamanetwork.com/data/Journals/DERM/5115/dst70043_58_64.pdf

References

  • MoleMap Internal Audit. Benign to malignant ratio from a sample of 700 recommended excisions from 2010-2013. Sensitivity from documentation of reported missed melanomas.
  • Youl, P. H et al. Diagnosing skin cancer in primary care: how do mainstream general practitioners compare with primary care skin cancer clinic doctors? Med J Aust 2007;187(4):215-220.
  • Scope A, et al. The “Ugly Duckling” Sign. Arch Dermatol. 2008;144(1):58-64.
  • * http://www.aihw.gov.au/cancer/melanoma/